2025 Neurotech Review: BCIs, Brain Delivery, Organoids and Neuro-AI Move Closer to Clinic

Invasive & Minimally Invasive BCIs

Brain-computer interface (BCI) systems are being explored and used as a way to restore lost motor, speech, or sensory functions, particularly in patients with paralysis or neurodegenerative conditions. They work by placing electrodes on or in the brain to capture high-resolution neural activity, which is then translated into actions like moving a cursor, generating speech, or triggering stimulation.

Typically, BCIs include implanted pulse generators and wireless connections to external processors, which decode brain signals such as spikes or local field potentials from targeted brain areas, then use trained algorithms to translate those activity patterns into outputs such as cursor motion, text, or stimulation commands.

In 2025, several programs moved into multi-center or early pivotal territory:

• Neuralink extended its PRIME program into Great Britain with the GB-PRIME study at UCLH and Newcastle, evaluating the fully implantable N1 interface in patients with motor neuron disease and spinal cord injury, and reporting the first UK patient controlling a computer within hours after surgery. The same implant was used at home by ALS patient Brad Smith to control a motorized Insta360 webcam, demonstrating extended real-world use beyond cursor control.
• Paradromics received FDA IDE approval for its Connexus system to start the Connect-One early feasibility study, targeting speech restoration and computer control in people with severe paralysis via a high-bandwidth, fully implantable BCI. The Connect-One trial is designed around speech restoration as a primary endpoint rather than generic cursor control.
• Precision Neuroscience advanced its thin-film Layer 7 cortical interface. The 1,024-electrode subdural array, FDA-cleared as a temporary mapping device, was profiled in first human recipients as a minimally invasive, high-density platform that sits on the cortical surface rather than penetrating tissue.
• CorTec’s Brain Interchange BCI system reached first-in-human use in a stroke patient as a fully wireless, closed-loop implant capable of recording and stimulating cortex in real time, positioning it as a European competitor in implantable neuromodulatory BCIs.
• Synchron introduced an updated version of its endovascular Stentrode BCI that integrates Nvidia AI and the Apple Vision Pro headset to let people with severe paralysis control digital and physical environments using neural signals. Later, Synchron publicly demonstrated a person with ALS using its implanted Stentrode to control an iPad entirely by thought by converting neural motor-intent signals into native iPadOS inputs.

Neuromodulation

Hybrids at the neuromodulation edge are being designed to blend brain implants with disease-monitoring electronics so a single system can both “listen” to pathological activity and deliver targeted stimulation. In epilepsy and movement disorders, implanted leads already record abnormal signals from dysfunctional circuits and use on-device algorithms to trigger stimulation in a closed loop. In this regard, INBRAIN Neuroelectronics announced a strategic collaboration with Microsoft to apply Azure’s time-series AI models and cloud infrastructure to its graphene-based cortical interfaces for adaptive, closed-loop neuromodulation for Parkinson’s disease and epilepsy.

Speech

Clinically focused speech BCIs also continue to mature. These interfaces record neural activity from speech and language areas of the cortex and translate patterns of intended words, syllables, or articulatory movements into synthesized audio or text. Instead of moving a cursor, the decoding models are trained directly on attempted speech, so users can “speak” by thinking of saying words even when their muscles can no longer produce sound.

• Neuralink’s implantable speech-restoration BCI received an FDA “breakthrough device” designation, which is intended to help people with severe speech impairment from conditions including ALS, stroke, spinal cord injury, cerebral palsy, and multiple sclerosis.
• Additionally, academic teams at UC Davis and collaborators demonstrated real-time synthesized speech in a patient with ALS using arrays implanted in speech-related cortex, part of a broader push toward high-rate decoding of intended speech.
• Another 2025 Nature Neuroscience study from UCSF and UC Berkeley described a streaming brain-to-voice neuroprosthesis that restored near-conversational, audible speech in a woman with long-standing paralysis, decoding continuous attempted speech in real time from an implanted cortical electrode array.

Noninvasive & Consumer-Grade BCIs

Noninvasive BCIs require no surgery, and use external sensors, typically EEG headsets or caps, to pick up tiny voltage changes on the scalp linked to brain activity. Machine-learning models decode these signals into commands for cursors, drones, or apps, trading signal fidelity for safety, accessibility, and easier deployment outside the operating room.

Recent invasive speech BCI studies report and , but all of these systems still depend on neurosurgical implantation of electrodes on or in cortex. That surgery restricts use to a small number of patients and brings perioperative and long-term hardware risks that limit broader deployment. The noninvasive work in 2025 is trying to push EEG, MEG and fNIRS closer to invasive BCI performance while avoiding the need for brain surgery altogether.